J&J multiple myeloma drug gains edge in earlier stage disease

J&J multiple myeloma drug gains edge in earlier stage disease is a pharma and life sciences industry update from BioPharma Dive. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

Delilah Alvarado · 2026-06-15

The latest results studying Talvey in combination with Darzalex Faspro support J&J’s efforts to expand the immunotherapy's use.

Source: BioPharma Dive